CBD oil image accompanying Valley CBD’s guide to CBD bioavailability and absorption

CBD Bioavailability UK: What Does the Research Show?

What Is CBD Bioavailability?

Bioavailability sounds complicated, but the basic idea is simple.

It describes how much of a substance reaches the bloodstream and becomes available to the body after it is taken.

For CBD, this can be affected by:

  • how the CBD is taken
  • the formulation it is dissolved in
  • whether it is taken with food
  • the amount consumed
  • individual differences between people.

This is why claims such as “CBD oil has 35% bioavailability” or “gummies only absorb 6%” should be treated cautiously.

Human studies do not support one fixed absorption percentage that applies to every CBD oil, gummy, capsule or person.

A major systematic review examining 112 trial arms from 39 human studies found that CBD pharmacokinetics varied substantially according to dose, route, formulation and whether people had eaten. Read the systematic review on PubMed.

What Is the Difference Between Bioavailability and Absorption?

The two terms are related but they are not identical.

Absorption refers to CBD moving from where it was taken into the body.

Bioavailability more specifically concerns the fraction that eventually reaches systemic circulation.

Researchers often measure this indirectly using pharmacokinetic measurements such as:

  • Cmax — the highest CBD concentration measured in the blood
  • Tmax — how long it takes to reach that peak
  • AUC — overall CBD exposure over time.

These measurements are useful, but they do not automatically tell us whether somebody will experience a particular effect.

That distinction is important.

More CBD in the bloodstream does not automatically mean greater health benefits.

Clinical effectiveness has to be demonstrated separately.

What Happens When CBD Is Swallowed?

When CBD is swallowed — for example in capsules, gummies, food or swallowed oil — it passes through the gastrointestinal tract before reaching systemic circulation.

CBD has relatively poor water solubility, and swallowed CBD can also undergo substantial first-pass metabolism, particularly in the liver.

That contributes to the considerable variability seen with oral CBD.

The kidneys are not the main reason swallowed CBD fails to reach the bloodstream. The more important issues are gastrointestinal absorption, formulation and metabolism in the gut and liver.

This is why two people taking the same labelled amount of CBD may not necessarily produce the same blood concentrations.

Is Sublingual CBD Absorbed Directly Into the Bloodstream?

The area underneath the tongue has a rich blood supply, so in principle compounds can be absorbed through the oral mucosa.

That is why CBD oils are frequently marketed for sublingual use.

The theory is that holding CBD under the tongue may allow some CBD to cross the oral mucosa before the remainder is swallowed.

However, the important question is not whether oral-mucosal absorption is biologically possible.

The important question is:

Does ordinary CBD oil held under the tongue actually produce substantially greater CBD exposure than swallowing it?

Current human evidence does not establish a large, consistent advantage.

What Did the Direct Sublingual vs Capsule Study Find?

A particularly useful randomized crossover study compared the same CBD oil administered in two different ways.

Eight healthy men received CBD oil either as sublingual drops or enclosed inside gelatin capsules and swallowed.

Researchers then measured CBD concentrations in the blood.

The results were remarkably similar.

Peak CBD concentration was approximately:

  • 28.0 ng/mL with capsules
  • 24.0 ng/mL with sublingual drops.

Both reached their average peak at approximately four hours.

Overall CBD exposure was also similar, and the researchers found no meaningful pharmacokinetic difference between the two conditions. Read the direct comparison on PubMed.

They suggested that much of the CBD oil placed under the tongue may ultimately have been swallowed before substantial oral-mucosal absorption occurred.

This was a small study involving only eight men, so it does not prove that sublingual administration never matters.

But it provides an important warning against claiming that ordinary sublingual CBD oil is automatically absorbed two, three or four times better than swallowed CBD.

What Does the Wider Research Say?

A larger systematic review and meta-regression examined 39 CBD pharmacokinetic studies containing 112 trial arms.

Researchers looked at CBD delivered through several routes and formulations, including oral, oromucosal, inhaled, oil-based, water-based, alcohol-based and nanotechnology formulations. Read the review on PubMed.

They found substantial differences according to CBD dose, route, formulation and food intake.

Interestingly, the analysis did not show oromucosal CBD universally outperforming oral administration.

In that dataset, oromucosal administration was associated with lower peak concentrations and overall exposure than oral administration.

This does not mean swallowing CBD is always superior either.

The included studies used many different doses and formulations, so a meta-regression cannot substitute for direct head-to-head trials.

What it does show very clearly is that the familiar internet claim “oral CBD = 6–15%, sublingual CBD = 20–35%” is much too simplistic.

Does This Mean Holding CBD Oil Under the Tongue Is Pointless?

No.

The research does not show that sublingual use is pointless.

It shows that we should not promise a specific absorption advantage that human evidence has not established.

Using CBD oil as drops still has practical characteristics that some consumers may prefer.

  • a liquid can be measured by volume
  • concentration can be clearly expressed in mg per ml
  • oils can contain relatively few ingredients
  • different oil concentrations can deliver different amounts in the same liquid volume
  • some people simply prefer drops to sweets or capsules.

Those are legitimate product differences.

They do not require us to claim that sublingual CBD is medically more effective.

CBD Oil vs Gummies: Which Has Better Bioavailability?

A gummy is swallowed.

Therefore, CBD in a gummy must pass through gastrointestinal absorption and is subject to the factors affecting swallowed CBD.

An oil placed underneath the tongue creates the possibility of some oral-mucosal absorption before the remainder is swallowed.

However, current human research does not allow us to say:

“CBD oil always delivers a higher percentage of CBD into your bloodstream than gummies.”

Gummy formulation also matters.

Food composition, fats, emulsifiers and other formulation technologies can influence how CBD is absorbed.

So the scientifically safer comparison is based on the characteristics we can actually establish.

CBD oils can provide:

  • clearly stated mg/ml concentration
  • liquid measurement
  • concentrated CBD in a small volume
  • relatively simple ingredient formulations.

Gummies generally provide:

  • a predetermined amount per gummy
  • a familiar food format
  • sweetness and flavour that mask CBD's taste
  • additional ingredients needed to create the gummy.

Our separate CBD Oil vs Gummies UK guide looks at those practical differences in more detail.

What About CBD Capsules?

Capsules are another swallowed format.

Like gummies, the CBD passes through the digestive tract.

But we should not assume that this automatically makes them dramatically less bioavailable than sublingual oil.

The direct study comparing CBD oil in gelatin capsules with the same oil as sublingual drops found similar blood CBD profiles. Read the study on PubMed.

That makes capsules a very useful example of why actual human pharmacokinetic studies are more valuable than repeating theoretical absorption percentages.

Does Food Change CBD Absorption?

Yes.

This is one of the clearest findings in CBD pharmacokinetic research.

CBD is fat-soluble, and food — particularly meals containing fat — can substantially alter systemic exposure to swallowed CBD.

A systematic review of food-effect studies found greater CBD exposure in fed participants than fasted participants. Read the food-effect review on PubMed.

Individual trials have demonstrated surprisingly large differences.

For example, one human crossover study of a CBD-rich extract reported substantially higher peak concentration and overall exposure after a high-fat meal than under fasting conditions. Read the study on PubMed.

Another more recent study using a nanodispersible CBD solution also found that food increased overall CBD exposure, although the size of the effect differed from other formulations. Read the recent study on PubMed.

The fact that different studies produce very different food effects tells us something important:

formulation matters enormously.

Should Everyone Therefore Take CBD With a High-Fat Meal?

That is not what these studies establish.

Pharmacokinetic studies tell us how food changed blood CBD concentrations in a particular experiment.

They do not automatically establish the best consumer routine or prove that greater CBD exposure produces better outcomes.

They also frequently use amounts of CBD very different from normal UK food-supplement use.

Therefore, Valley CBD should not turn a food-effect study into instructions designed to maximise someone's systemic exposure.

The useful consumer message is simply that food can materially alter CBD absorption, which is another reason fixed bioavailability percentages are unreliable.

Why Does the CBD Formulation Matter?

CBD is highly lipophilic, meaning it has an affinity for fats rather than water.

Manufacturers therefore use different delivery systems to carry CBD.

Examples studied by researchers include oils, alcohol-based solutions, water-compatible systems, emulsions, nanoformulations and pharmaceutical preparations.

Changing the formulation can alter how quickly CBD is absorbed, peak blood concentration, total CBD exposure and variability between people.

The large pharmacokinetic review found formulation to be an important source of variation and reported faster absorption with some nanotechnology formulations. Read the review on PubMed.

That does not mean every product marketed as “nano CBD” is automatically superior.

Nor does it mean results from a specialised clinical formulation apply to an ordinary retail CBD oil.

Does MCT Oil Affect CBD Absorption?

MCT oil is commonly used as a CBD carrier because CBD dissolves readily into oils.

Valley CBD oils use an MCT-based carrier.

However, we should distinguish that factual product characteristic from a clinical claim.

We should not say “our MCT oil makes Valley CBD more bioavailable” unless the finished Valley CBD formulation itself has been tested against an appropriate comparator.

A carrier oil may influence formulation and digestion, but studies of other products cannot establish an exact bioavailability figure for Valley CBD oil.

What About CBD Balms and Creams?

Topical and transdermal products need another important distinction.

A topical product is generally intended to be applied to the skin.

A transdermal formulation is specifically engineered to deliver an ingredient across the skin into systemic circulation.

These are not interchangeable terms.

The old Valley CBD bioavailability article said topical CBD had systemic bioavailability close to zero.

That is too absolute.

Research shows that skin penetration varies considerably depending on the formulation, and specialised transdermal systems may produce measurable systemic exposure.

But that evidence should not be used to claim that an ordinary retail CBD balm produces systemic CBD concentrations.

A balm and an oral CBD oil therefore should not be compared using one simplistic percentage.

What About Inhaled CBD?

Inhalation can produce relatively rapid CBD delivery into the bloodstream because it avoids gastrointestinal absorption.

That is pharmacologically interesting.

However, Valley CBD does not sell inhaled CBD products, and we do not need to recommend vaping as a way to maximise CBD bioavailability.

The purpose of discussing it here is simply to show that route of administration affects pharmacokinetics.

This article is not a ranking of ways to consume as much CBD as possible.

Does Higher Bioavailability Mean CBD Works Better?

No.

This is perhaps the most important correction to the old article.

Bioavailability is a pharmacokinetic concept.

It tells researchers about exposure to a compound.

It does not by itself prove greater pain relief, better sleep, less anxiety, better recovery, stronger wellness effects or greater medical effectiveness.

To establish an actual health benefit, researchers need appropriate clinical trials measuring that outcome.

A product cannot reasonably claim to provide “better effects” simply because it produces a higher blood concentration.

Does More CBD in the Blood Mean You Need Less CBD?

Not necessarily.

Again, pharmacokinetics and clinical effectiveness are different questions.

If two formulations produce different CBD concentrations in blood, researchers can measure that difference.

But it does not automatically tell a consumer “you need X% less of this product to get the same result.”

That would require clinical evidence demonstrating the relevant result and comparing the products appropriately.

This is why we are removing the old Valley CBD statements that implied greater absorption automatically means a smaller amount is needed for the same effect.

Why Do CBD Bioavailability Figures Vary So Much?

The formulation

Different oils, emulsions and pharmaceutical preparations can behave differently.

Food

Fed versus fasted conditions can dramatically alter CBD exposure.

Dose

Higher CBD doses generally produce higher blood concentrations, although the relationship may not always be perfectly proportional.

Route

Swallowed, oromucosal, inhaled and specially engineered transdermal formulations behave differently.

The individual

Body composition, sex, metabolism and other biological differences may contribute to variation.

Study design

Some experiments measure CBD for only a few hours, while others follow concentrations for much longer.

This makes it misleading to take one number from one study and label it “the bioavailability of CBD oil.”

Why Doesn't Valley CBD Publish a Bioavailability Percentage?

Because Valley CBD's finished retail oils have not undergone a clinical pharmacokinetic study that would allow us to establish one.

The honest approach is to state what we know about the products themselves — such as CBD concentration, bottle size, CBD-isolate formulation and carrier ingredients — and use independent human research to explain CBD pharmacokinetics generally.

That keeps product facts separate from scientific evidence.

How Does UK CBD Safety Guidance Fit In?

Bioavailability research sometimes uses CBD doses far above normal consumer-food guidance.

Those research doses should not be converted into consumer instructions.

The UK Food Standards Agency currently advises healthy adults to limit CBD from foods to 10mg per day from all food sources. Read current FSA guidance.

That 10mg figure is safety guidance.

It is not a dose proven to produce a particular benefit, a recommended treatment dose or a bioavailability target.

The FSA also advises certain groups to avoid consuming CBD, including children, people who are pregnant or breastfeeding, people trying to conceive, people taking medication and people with underlying health conditions unless under medical direction. Read the FSA's 2026 advice.

Frequently Asked Questions

What is CBD bioavailability?

CBD bioavailability describes the extent to which CBD reaches systemic circulation after administration.

Researchers usually assess this using blood-concentration measurements such as Cmax and AUC.

What percentage of CBD oil is absorbed?

There is no single reliable percentage that applies to all CBD oils.

Dose, formulation, food, route and individual biology can all alter CBD exposure.

Is sublingual CBD more bioavailable than swallowed CBD?

It is often claimed to be, but direct human evidence does not establish a large universal advantage.

One randomized crossover study found very similar CBD blood profiles when the same CBD oil was taken as sublingual drops or swallowed inside capsules. Read the study on PubMed.

Is 20–35% sublingual CBD bioavailability proven?

No.

It should not be presented as a universal established figure for consumer CBD oils.

Are CBD gummies poorly absorbed?

Swallowed CBD is affected by gastrointestinal absorption and first-pass metabolism, but gummy bioavailability cannot be reduced to one universal percentage.

The formulation and whether the product is consumed with food can make a substantial difference.

Does CBD oil bypass the liver?

Not completely.

Even when oil is held underneath the tongue, some or much of it may ultimately be swallowed.

A direct study found similar CBD pharmacokinetics between sublingual drops and swallowed capsules.

Does eating affect CBD absorption?

Yes.

Human pharmacokinetic research shows food can substantially change CBD concentrations in blood, although the size of this effect varies between formulations and studies.

Does higher bioavailability mean stronger effects?

Not necessarily.

Greater systemic exposure is a pharmacokinetic finding. It does not by itself demonstrate greater clinical effectiveness.

Is CBD oil better than gummies?

Neither format is universally “better”.

CBD oils allow liquid measurement and potentially very high CBD concentration in a small volume, while gummies provide a fixed food format.

Current human evidence does not establish that ordinary sublingual CBD oil universally delivers more CBD into the bloodstream than all swallowed products.

How long does CBD take to reach the bloodstream?

There is no one timing figure for all CBD products.

Tmax varies by dose, formulation, food and route.

In the direct sublingual-drops versus capsule study, peak CBD concentrations occurred at about four hours in both conditions.

That does not mean every CBD product always peaks at four hours.

Does Valley CBD have a tested bioavailability figure?

No.

Valley CBD's finished retail oils have not been clinically tested to establish a product-specific bioavailability percentage, so we do not claim one.

The Bottom Line

CBD bioavailability is more complicated than the percentages commonly repeated online.

Swallowed CBD can be affected by gastrointestinal absorption and first-pass metabolism.

Sublingual administration provides a theoretical opportunity for CBD to enter through the oral mucosa.

But direct human research does not currently justify claiming that ordinary CBD oil held under the tongue is automatically absorbed several times better than swallowed CBD.

One direct randomized comparison found very similar CBD blood profiles between sublingual CBD oil and the same oil swallowed in capsules.

A much larger systematic review shows why simple numbers are unreliable: CBD exposure varies with dose, route, formulation and food intake.

Food alone can change systemic exposure by several-fold in some studies.

So rather than promising a particular absorption percentage, the evidence supports a more useful conclusion:

CBD pharmacokinetics depend heavily on how a product is formulated and used, and higher blood exposure should not automatically be interpreted as greater health benefits.

This article is for general educational information only and is not medical advice. Valley CBD products are not intended to diagnose, treat, cure or prevent disease.

Sources

Back to blog